Vaxcyte, Inc.
PCVX
$30.25
-$0.20-0.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.12% | -16.67% | -15.33% | -69.49% | -87.78% |
| Total Depreciation and Amortization | 59.53% | 61.43% | 55.79% | 47.10% | 27.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 107.61% | 270.16% | 260.03% | 125.42% | 13.38% |
| Change in Net Operating Assets | 213.92% | -4,376.50% | -167.50% | -135.90% | -157.77% |
| Cash from Operations | 1.57% | -12.63% | -52.51% | -101.56% | -117.96% |
| Capital Expenditure | 9.39% | -80.03% | -75.55% | -1,122.93% | -2,015.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -186.64% | -84.84% | -167.43% | -68.02% | 47.56% |
| Cash from Investing | -143.37% | -84.38% | -159.36% | -83.87% | 33.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 56.05% | 15.77% | 282.61% | 89.62% | -23.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -141.38% | -152.15% | -268.73% | -281.75% | -277.69% |
| Cash from Financing | 55.45% | 15.15% | 282.69% | 89.09% | -23.99% |
| Foreign Exchange rate Adjustments | -13.90% | -589.95% | 106.37% | -580.25% | -349.24% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,645.20% | -214.33% | 97.86% | 89.26% | -104.14% |